METTL1 and intrahepatic cholangiocarcinoma: Experimental studies in preclinical mouse models of ICC have revealed that pharmacological or genetic inhibition of METTL1 enhances the therapeutic potency of anti‐PD‐1 immunotherapy, suggesting a potential synergistic therapeutic strategy.141